Covered recipient · General Payments record
VIKRAM AS SAHNI
Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$108,200.00
58 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $108,200.00 | 58 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $106,600.00 | 57 |
| Seagen Inc. | $1,600.00 | 1 |
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VIKRAM AS SAHNI
NPI 1871739946 · CMS profile ID 843451
Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology
WELLESLEY, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1871739946?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VIKRAM AS SAHNI, NPI 1871739946, CMS profile ID 843451. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871739946?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). VIKRAM AS SAHNI, NPI 1871739946, CMS profile ID 843451. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871739946?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- VIKRAM AS SAHNI, NPI 1871739946, CMS profile ID 843451, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1871739946?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
58 matching records · $108,200.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–58 of 58.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $70.00 | 03/02/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614903 | CMS |
| Merck Sharp & Dohme Corporation | $435.00 | 01/27/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614901 | CMS |
| Merck Sharp & Dohme Corporation | $805.00 | 01/27/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614921 | CMS |
| Merck Sharp & Dohme Corporation | $1,800.00 | 01/21/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614867 | CMS |
| Merck Sharp & Dohme Corporation | $3,305.00 | 01/21/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614897 | CMS |
| Merck Sharp & Dohme Corporation | $2,270.00 | 01/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614871 | CMS |
| Merck Sharp & Dohme Corporation | $325.00 | 01/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614895 | CMS |
| Merck Sharp & Dohme Corporation | $1,170.00 | 01/02/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747614863 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021
- Generated from
- OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $137,705.00 | 57 |
| PY2024 | Principal investigator | $108,884.11 | 35 |
| PY2023 | Principal investigator | $228,993.18 | 47 |
| PY2022 | Principal investigator | $181,310.00 | 37 |
| PY2021 | Principal investigator | $188,720.98 | 100 |
| PY2020 | Principal investigator | $189,164.46 | 89 |
| PY2019 | Principal investigator | $219,628.65 | 80 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
57 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca UK Limited | $3,340.00 | 12/16/2025 | Non-covered Recipient Entity VX3 IMAGING PC | This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III | No dispute reported | 06/30/2026 | 1185543971 |
| Principal investigator 1 | Geron Corporation | $375.00 | 12/16/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238897200 |
| Principal investigator 1 | Novartis Pharma AG | $180.00 | 12/16/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108931 |
| Principal investigator 1 | BeOne Medicines Ltd. | $565.00 | 12/02/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190344740 |
| Principal investigator 1 | Geron Corporation | $75.00 | 12/02/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238896942 |
| Principal investigator 1 | Novartis Pharma AG | $655.00 | 12/02/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108929 |
| Principal investigator 1 | ABBVIE INC. | $85.00 | 11/25/2025 | Non-covered Recipient Entity PERITUS IMAGING INC | Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | No dispute reported | 06/30/2026 | 1202525274 |
| Principal investigator 1 | ABBVIE INC. | $3,240.00 | 11/25/2025 | Non-covered Recipient Entity PERITUS IMAGING INC | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinibnib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) | No dispute reported | 06/30/2026 | 1202525276 |
| Principal investigator 1 | ABBVIE INC. | $6,180.00 | 10/28/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202518709 |
| Principal investigator 1 | ABBVIE INC. | $220.00 | 10/28/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | No dispute reported | 06/30/2026 | 1202518875 |
| Principal investigator 1 | Geron Corporation | $225.00 | 10/28/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238896392 |
| Principal investigator 1 | Novartis Pharma AG | $205.00 | 10/28/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248109011 |
| Principal investigator 1 | ABBVIE INC. | $2,175.00 | 09/23/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202511860 |
| Principal investigator 1 | ABBVIE INC. | $2,920.00 | 09/23/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202511862 |
| Principal investigator 1 | Geron Corporation | $225.00 | 09/23/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238896063 |
| Principal investigator 1 | Novartis Pharma AG | $630.00 | 09/23/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248109013 |
| Principal investigator 1 | ABBVIE INC. | $3,120.00 | 08/19/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202505041 |
| Principal investigator 1 | ABBVIE INC. | $1,725.00 | 08/19/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202505043 |
| Principal investigator 1 | BeOne Medicines Ltd. | $450.00 | 08/19/2025 | Non-covered Recipient Entity VX3 IMAGING PC | An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190341465 |
| Principal investigator 1 | Geron Corporation | $150.00 | 08/19/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238895908 |
| Principal investigator 1 | Novartis Pharma AG | $1,445.00 | 08/19/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108921 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 07/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498264 |
| Principal investigator 1 | ABBVIE INC. | $1,600.00 | 07/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202498266 |
| Principal investigator 1 | ABBVIE INC. | $1,600.00 | 07/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | No dispute reported | 06/30/2026 | 1202498268 |
| Principal investigator 1 | BeOne Medicines Ltd. | $270.00 | 07/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190341461 |
| Principal investigator 1 | Geron Corporation | $225.00 | 07/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238895650 |
| Principal investigator 1 | Novartis Pharma AG | $2,730.00 | 07/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108923 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 06/17/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491683 |
| Principal investigator 1 | BeOne Medicines Ltd. | $810.00 | 06/17/2025 | Non-covered Recipient Entity VX3 IMAGING PC | An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190327027 |
| Principal investigator 1 | Geron Corporation | $375.00 | 06/17/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238895370 |
| Principal investigator 1 | Novartis Pharma AG | $2,700.00 | 06/17/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108933 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 05/20/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485525 |
| Principal investigator 1 | AstraZeneca UK Limited | $3,390.00 | 05/20/2025 | Non-covered Recipient Entity VX3 IMAGING PC | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer | No dispute reported | 06/30/2026 | 1185543965 |
| Principal investigator 1 | BeiGene, Ltd. | $1,690.00 | 05/20/2025 | Non-covered Recipient Entity VX3 IMAGING PC | An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190323188 |
| Principal investigator 1 | Geron Corporation | $375.00 | 05/20/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238895223 |
| Principal investigator 1 | Novartis Pharma AG | $540.00 | 05/20/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108927 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 04/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202476427 |
| Principal investigator 1 | BeiGene, Ltd. | $90.00 | 04/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190321422 |
| Principal investigator 1 | Geron Corporation | $525.00 | 04/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor | No dispute reported | 06/30/2026 | 1238894411 |
| Principal investigator 1 | Novartis Pharma AG | $410.00 | 04/15/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248109009 |
| Principal investigator 1 | ABBVIE INC. | $225.00 | 03/27/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202466477 |
| Principal investigator 1 | ABBVIE INC. | $375.00 | 03/27/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202466513 |
| Principal investigator 1 | ABBVIE INC. | $700.00 | 03/27/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467100 |
| Principal investigator 1 | BeiGene, Ltd. | $180.00 | 03/27/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies | No dispute reported | 06/30/2026 | 1190323222 |
| Principal investigator 1 | Novartis Pharma AG | $385.00 | 03/27/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108935 |
| Principal investigator 1 | ABBVIE INC. | $4,460.00 | 02/18/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452443 |
| Principal investigator 1 | BeiGene, Ltd. | $450.00 | 02/18/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies | No dispute reported | 06/30/2026 | 1190323220 |
| Principal investigator 1 | Novartis Pharma AG | $205.00 | 02/18/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248108925 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202440333 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202440336 |
| Principal investigator 1 | ABBVIE INC. | $3,120.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440467 |
| Principal investigator 1 | AstraZeneca UK Limited | $14,120.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1185543961 |
| Principal investigator 1 | AstraZeneca UK Limited | $30,260.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 1185543963 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,180.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN) | No dispute reported | 06/30/2026 | 1185543967 |
| Principal investigator 1 | AstraZeneca UK Limited | $26,570.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) | No dispute reported | 06/30/2026 | 1185543969 |
| Principal investigator 1 | BeiGene, Ltd. | $90.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies | No dispute reported | 06/30/2026 | 1190323218 |
| Principal investigator 1 | Novartis Pharma AG | $205.00 | 01/21/2025 | Non-covered Recipient Entity VX3 IMAGING PC | CTL019E2301 | No dispute reported | 06/30/2026 | 1248109007 |